Copeptin in heart failure: Review and meta-analysis

Area of Science:

• Cardiology
• Biomarkers
• Prognostic research

Background:

• Heart failure (HF) is a significant cause of mortality worldwide.
• Accurate prognostic markers are crucial for managing HF patients.
• Copeptin's role in predicting mortality in HF requires further elucidation.

Purpose of the Study:

• To systematically evaluate the prognostic value of copeptin for predicting all-cause mortality in patients with heart failure (HF).
• To compare the predictive performance of copeptin with established biomarkers like NT-proBNP.

Main Methods:

• A systematic literature search was conducted across PubMed, Embase, and Cochrane databases.
• Meta-analysis techniques, including forest plots and SROC curves, were used to summarize test performance.
• Heterogeneity was assessed using the Q-test and I² index.

Main Results:

• Ten prospective cohort studies with 4473 patients were included.
• Elevated copeptin levels significantly increased the risk of all-cause mortality in HF patients (RR 2.64).
• Pooled sensitivity and specificity for copeptin were 0.57 and 0.74, respectively, with an AUC of 0.70, comparable to NT-proBNP (AUC 0.71).

Conclusions:

• Elevated copeptin is a significant predictor of all-cause mortality in heart failure patients.
• Copeptin demonstrates a prognostic performance comparable to NT-proBNP in HF.
• Further research is recommended to explore combined biomarker use and optimal cut-off levels for copeptin.